Showing 3441-3450 of 18626 results for "".
Treatment of a Broader Population of Patients With DMD
https://reachmd.com/programs/cme/treatment-of-a-broader-population-of-patients-with-dmd/33167/By completing this activity, learners will gain the skills and confidence to determine therapeutic candidacy and conduct appropriate assessments for patients with Duchenne Muscular Dystrophy (DMD) across the age spectrum, including older and non-ambulatory individuals. They will improve their abilitLet’s Rewind: Recognizing NAFLD/NASH in the Primary Care Clinic
https://reachmd.com/programs/cme/lets-rewind-recognizing-nafldnash-in-the-primary-care-clinic/16020/Are you thinking NAFLD? As emerging therapies become available, PCPs need to be prepared to accurately identify patients at risk for NAFLD or NASH.Mechanistic Evolution in RAS Therapy: ON-State and Multi-Selective Targeting
https://reachmd.com/programs/cme/mechanistic-evolution-in-ras-therapy-on-state-and-multi-selective-targeting/54120/Explore ON-state RAS inhibitors for the treatment of NSCLC and pancreatic cancer, including mechanisms, efficacy data, and integration into clinical practice.Novel RAS-Targeted Therapy: Prevention, Monitoring, and Mitigation of Adverse Events
https://reachmd.com/programs/cme/novel-ras-targeted-therapy-prevention-monitoring-and-mitigation-of-adverse-events/54123/Explore ON-state RAS inhibitors for the treatment of NSCLC and pancreatic cancer, including mechanisms, efficacy data, and integration into clinical practice.Unmet Need: Second-Line Outcomes Remain Poor for NSCLC and Pancreatic Cancer
https://reachmd.com/programs/cme/unmet-need-second-line-outcomes-remain-poor-for-nsclc-and-pancreatic-cancer/54118/Explore ON-state RAS inhibitors for the treatment of NSCLC and pancreatic cancer, including mechanisms, efficacy data, and integration into clinical practice.New Pathways in the Treatment of DMD
https://reachmd.com/programs/cme/new-pathways-in-the-treatment-of-dmd/48924/The Duchenne muscular dystrophy (DMD) treatment landscape continues to evolve, with promising therapies emerging from new insights into disease biology. This activity explores the role of aberrant histone deacetylase (HDAC) activity in DMD pathophysiology, including its impact on inflammation, musclFuture Directions of Ovarian Function Suppression: Answering Unmet Needs in Premenopausal HR+ Early-Stage Breast Cancer
https://reachmd.com/programs/cme/future-directions-of-ovarian-function-suppression-answering-unmet-needs-in-premenopausal-hr-early-stage-breast-cancer/32909/Optimize ovarian function suppression in HR+ early-stage breast cancer with expert insights on timing and duration to enhance patient outcomes.Expert Consensus on Physical Therapy for Acute and Sub-Acute Low Back Pain
https://reachmd.com/programs/clinicians-roundtable/expert-consensus-on-physical-therapy-for-acute-and-sub-acute-low-back-pain/26729/What are some effective interventions for managing low back pain? That’s the exact question an expert consensus sought to answer; here are the results.The Role of Hemodynamics for AKI and Maintaining Hemodynamic Stability in KRT Patients
https://reachmd.com/programs/kdigo-conversations-nephrology/the-role-of-hemodynamics-for-aki-and-maintaining-hemodynamic-stability-in-krt-patients/14170/What is the role of hemodynamics in patients with acute kidney injury? And why is it important to maintain hemodynamic stability during KRT?Management of POSEIDON Groups 3-4
https://reachmd.com/programs/global-womens-health-academy/management-poseidon-groups-3-4/9919/Dr. Humaidan presents the POSEIDON classification, including detailed discussion of groups 3 and 4.